Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria

Expert Opinion on Drug Metabolism and Toxicology

Volumn 13, Issue 7, 2017, Pages 705-714

  Abdelraouf, Kamilia ^a   Linder, Kristin E ^a   Nailor, Michael D ^a,b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

fluoroquinolones; MPC; PK PD; polymyxins; resistance; lactams

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM DERIVATIVE; POLYMYXIN DERIVATIVE; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; GRAM NEGATIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETIC PARA; PREDICTION; REVIEW; ANIMAL; COMBINATION DRUG THERAPY; DRUG DESIGN; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 85021797194     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2017.1329417     Document Type: Review

References (61)

1. CDC. Antibiotic resistance threats in the United States:centers for Disease Control and Prevention, U.S. Department of Health and Human Services; Atlanta, GA, USA. 2013. Available from:https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
2. Ventola CL., The antibiotic resistance crisis:part 1:causes and threats. P T. 2015 Apr;40:277–283.
3. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria:an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.
4. Ventola CL., The antibiotic resistance crisis:part 2:management strategies and new agents. P T. 2015 May;40:344–352.
5. Boucher HW, Talbot GH, Benjamin DK, et al. 10 x ´20 Progress–development of new drugs active against gram-negative bacilli:an update from the infectious diseases society of America. Clin Infect Dis. 2013;56:1685–1694.
6. Linder KE, Nicolau DP, Nailor MD. Predicting and preventing antimicrobial resistance utilizing pharmacodynamics:part I gram positive bacteria. Expert Opin Drug Metab Toxicol. 2016;12:267–280.
7. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61:377–392.
8. Hooper DC. Mechanisms of action of antimicrobials:focus on fluoroquinolones. Clin Infect Dis. 2001 Mar 15;32(Suppl 1):S9–S15.
9. Ambrose PG, Bhavnani SM, Owens RC, Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am. 2003 Sep;17:529–543.
10. Leggett JE, Ebert S, Fantin B, et al. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis Suppl. 1990;74:179–184.
11. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073–1081.
12. Madaras-Kelly KJ, Ostergaard BE, Hovde LB, et al. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 1996;40:627–632.
13. Scaglione F, Mouton JW, Mattina R, et al. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model:peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob Agents Chemother. 2003;47:2749–2755.
14. Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987;31:1054–1060.
15. Peloquin CA, Cumbo TJ, Nix DE, et al. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med. 1989;149:2269–2273.
16. Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993;37:483–490.
17. Louie A, Heine HS, VanScoy B, et al. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance. Antimicrob Agents Chemother. 2011;55:822–830.
18. MacGowan AP, Rogers CA, Holt HA, et al. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 2003;47:1088–1095.
19. 24/MIC ratio among acutely ill patients from four clinical trials of nosocomial lower respiratory tract infections.
20. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients:results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother. 1994;38:547–557.
21. Louie A, Fregeau C, Liu W, et al. Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection:determination of epithelial lining fluid targets. Antimicrob Agents Chemother. 2009;53:3325–3330.
22. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003 Jul;112:275–285.•• The authors demonstrated that the likelihood of achieving resistance suppression exposures of fluoroquinolone against P. aeruginosa in humans with the clinically prescribed doses ranged between 24% and 61.8%, which was consistent with the resistance rates reported for P. aeruginosa in clinical settings.
23. Tam VH, Louie A, Deziel MR, et al. Bacterial-population responses to drug-selective pressure:examination of garenoxacin’s effect on Pseudomonas aeruginosa. J Infect Dis. 2005 Aug;1(192):420–428.
24. Firsov AA, Smirnova MV, Strukova EN, et al. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window:bolus versus continuous infusion. Int J Antimicrob Agents. 2008;32:488–493.
25. Liang B, Bai N, Cai Y, et al. Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55:2409–2412.
26. Homma T, Hori T, Sugimori G, et al. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2007;51:3810–3815.
27. Croisier D, Etienne M, Piroth L, et al. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia:impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother. 2004;54:640–647.
28. Firsov AA, Strukova EN, Shlykova DS, et al. Bacterial resistance studies using in vitro dynamic models:the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations. Antimicrob Agents Chemother. 2013;57:4956–4962.
29. Firsov AA, Vostrov SN, Lubenko IY, et al. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:1604–1613.
30. Strukova EN, Portnoy YA, Romanov AV, et al. Searching for the optimal predictor of ciprofloxacin resistance in klebsiella pneumoniae by using in vitro dynamic models. Antimicrob Agents Chemother. 2015;60:1208–1215.
31. Olofsson SK, Marcusson LL, Komp Lindgren P, et al. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model:relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother. 2006;57:1116–1121.
32. Olofsson SK, Marcusson LL, Stromback A, et al. Dose-related selection of fluoroquinolone-resistant Escherichia coli. J Antimicrob Chemother. 2007;60:795–801.
33. Ni W, Song X, Cui J. Testing the mutant selection window hypothesis with Escherichia coli exposed to levofloxacin in a rabbit tissue cage infection model. Eur J Clin Microbiol Infect Dis. 2014 Mar;33:385–389.
34. Mirelman D, Nuchamowitz Y. Biosynthesis of peptidoglycan in Pseudomonas aeruginosa. 2. Mode of action of beta-lactam antibiotics. Febs J. 1979 Mar;94:549–556.
35. Pechere JC, Kohler T. Patterns and modes of beta-lactam resistance in Pseudomonas aeruginosa. Clin Microbiology Infection:Official Publication Eur Soc Clin Microbiol Infect Dis. 1999 Mar;5(Suppl 1):S15–S18.
36. Strateva T, Yordanov D. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Med Microbiol. 2009 Sep;58(Pt 9):1133–1148.
37. Falagas ME, Tansarli GS, Ikawa K, et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam:a systematic review and meta-analysis. Clin Infect Dis. 2013;56:272–282.
38. Bauer KA, West JE, O’Brien JM, et al. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013;57:2907–2912.
39. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998 Jul;27:10–22.
40. Macvane SH, Crandon JL, Nicolau DP. Characterizing in vivo pharmacodynamics of carbapenems against Acinetobacter baumannii in a murine thigh infection model to support breakpoint determinations. Antimicrob Agents Chemother. 2014;58:599–601.
41. Tam VH, Schilling AN, Melnick DA, et al. Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2005 Jun;52:145–151.• This study provided some evidence that the different β-lactam subclasses vary in their propensities to suppress resistance emergence.
42. Eng RH, Smith SM, Cherubin C. Inoculum effect of new beta-lactam antibiotics on Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984 Jul;26:42–47.
43. Ong DS, Jongerden IP, Buiting AG, et al. Antibiotic exposure and resistance development in Pseudomonas aeruginosa and Enterobacter species in intensive care units. Crit Care Med. 2011;39:2458–2463.
44. Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa:comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43:1379–1382.
45. Tam VH, Schilling AN, Neshat S, et al. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49:4920–4927.
46. Stearne LE, Goessens WH, Mouton JW, et al. Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection. Antimicrob Agents Chemother. 2007;51:3605–3611.
47. Tam VH, Ledesma KR, Schilling AN, et al. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagn Microbiol Infect Dis. 2009;64:427–433.
48. Henrichfreise B, Wiegand I, Luhmer-Becker I, et al. Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro. Antimicrob Agents Chemother. 2007;51:3642–3649.
49. Louie A, Bied A, Fregeau C, et al. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother. 2010;54:2638–2645.
50. Luyt CE, Aubry A, Lu Q, et al. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014;58:1372–1380.
51. MSW ratio could be useful parameters for predicting suppression of meropenem resistance.
52. Crandon JL, Luyt CE, Aubry A, et al. Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia:associations with clinical outcome and recurrence. J Antimicrob Chemother. 2016;71:2534–2537.
53. Velkov T, Thompson PE, Nation RL, et al. Structure–activity relationships of polymyxin antibiotics. J Med Chem. 2010 Mar;11(53):1898–1916.
54. Kwa AL, Tam VH, Falagas ME. Polymyxins:a review of the current status including recent developments. Ann Acad Med Singapore. 2008 Oct;37:870–883.
55. Ko KS, Suh JY, Kwon KT, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007;60:1163–1167.
56. Landman D, Bratu S, Alam M, et al. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother. 2005;55:954–957.
57. Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Sep;49:3624–3630.•• Using an IVHFIM, the authors provided evidence that a polymyxin B dose that was 8 times higher than the standard clinical dose was needed to effectively suppress resistance emergence in wild-type P. aeruginosa.
58. Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother. 2010;54:1117–1124.
59. Dudhani RV, Turnidge JD, Nation RL, et al. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother. 2010;65:1984–1990.
60. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2007 Sep;51:3413–3415.•• The authors demonstrated that clinically relevant colistin exposures were associated with extensive regrowth of resistant A. baumannii mutants as early as 6 h from the initiation of the colistin regimens.
61. Bergen PJ, Bulman ZP, Landersdorfer CB, et al. Optimizing polymyxin combinations against resistant gram-negative bacteria. Infect Dis Ther. 2015;4:391–415.